Merck Serono, Strategic Innovation & Research & Portfolio Management (Switzerland)

Merck Serono, Strategic Innovation & Research & Portfolio Management

About Merck SERONO

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates. Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets. With an annual R&D expenditure of more than € 1 billion, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

NanoDiaRA collaborators

Associate Director Alliance Management Research

Principal Scientist, Head of Laboratory

Contact

MERCK SERONO HEADQUARTERS
Merck Serono S.A.
9, chemin des Mines
Case postale 54
1211 Geneva 20
Switzerland

Phone: +41 22 414 3000
Fax: +41 22 414 2179
michel.dreano|please replace this part with an email-at|merckserono.net
sven.lindemann|please replace this part with an email-at|merck.de
www.merckserono.com

create PDF of this page
News

Final Project Group Meeting in Leuven

19 February, 2014
Further information

NANOFOL – NanoDiaRA Conference in the 7th Framework Programme

20–21 November, 2013
Further information

Public conference: Nanoparticles for early diagnostics of inflammatory diseases - new approaches in the field of soft and hard nanoparticles

20–21 November, 2013
Further information

 

Find more news in the news archive.

Contact

Administrative Coordination

Priv.-Doz. Dr. med. Felix Thiele, M. Sc.
Europäische Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH
Wilhelmstr. 56
53474 Bad Neuenahr-Ahrweiler
Germany

felix.thiele|please replace this part with an email-at|ea-aw.de
www.ea-aw.org

Europäische Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH

Scientific Coordination

Margarethe Hofmann-Amtenbrink Dr.-Ing.
Mat Search Consulting Hofmann

Ch. Jean Pavillard 14
1009 Pully
Switzerland

mhofmann|please replace this part with an email-at|matsearch.ch
www.matsearch.ch

Mat Search Consulting Hofmann